Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

2-hydroxyoleic acid: a new hypotensive molecule.

Regina Alemany1, Silvia Terés, Carmela Baamonde

  • 1Laboratory of Molecular and Cellular Biomedicine, IUNICS, Department of Biology, Associate Unit of the Instituto de la Grasa, University of the Balearic Islands, Palma de Mallorca, Spain.

Hypertension (Dallas, Tex. : 1979)
|December 10, 2003
PubMed
Summary

A synthetic oleic acid derivative, 2-hydroxyoleic acid (2-OHOA), significantly lowered blood pressure (BP) in rats by increasing G-protein signaling. This discovery may lead to new antihypertensive drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipidomic Analysis of Human Plasma and Hippocampus Across Alzheimer's Progression and Preclinical 5xFAD Mouse Model.

Molecular neurobiology·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Fat for thought: Lipid regulation of neural stem cell fate.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection.

OncoTargets and therapy·2025
Same author

Deciphering WNT Signalling Vulnerabilities in Soft Tissue Sarcoma.

Pathobiology : journal of immunopathology, molecular and cellular biology·2025
Same author

Targeting the Notch-Furin axis with 2-hydroxyoleic acid: a key mechanism in glioblastoma therapy.

Cellular oncology (Dordrecht, Netherlands)·2024

Area of Science:

  • Cardiovascular Pharmacology
  • Molecular Biology
  • Hypertension Research

Background:

  • Diets rich in monounsaturated fatty acids (MUFAs), like oleic acid from olive oil, benefit blood pressure (BP) in hypertensive patients.
  • Oleic acid is a natural MUFA with known cardiovascular benefits.
  • Investigating synthetic MUFA derivatives for therapeutic potential is a growing area of research.

Purpose of the Study:

  • To determine if 2-hydroxyoleic acid (2-OHOA), a synthetic MUFA derivative, can regulate blood pressure (BP) in Sprague-Dawley rats.
  • To explore the molecular mechanisms underlying 2-OHOA's effects on BP.
  • To assess the potential of 2-OHOA as a novel antihypertensive agent.

Main Methods:

  • Administration of 2-OHOA (intraperitoneal and oral) to Sprague-Dawley rats.

Related Experiment Videos

  • Measurement of systolic and diastolic blood pressure and heart rate over time.
  • Analysis of G-protein (Galpha(s), Galpha(i2), Galpha(o), Galpha(q)/11) and protein kinase Calpha density in heart and aorta membranes.
  • Assessment of cAMP levels and adenylyl cyclase activity following receptor stimulation and inhibition.

    • Main Results:

    • 2-OHOA administration induced significant, sustained reductions in systolic BP (20-26 mm Hg) without affecting heart rate.
    • Increased density of Galpha(s) proteins in heart and aorta membranes, and Galpha(q)/11 and PKCalpha in heart membranes.
    • Enhanced cAMP production in response to Galpha(s) protein and beta-adrenergic receptor stimulation in treated rats.
    • No change in the inhibitory effect of hormones on adenylyl cyclase activity.

    Conclusions:

    • 2-OHOA effectively lowers blood pressure in rats through a mechanism involving enhanced Galpha(s) signaling and increased cAMP production.
    • The observed molecular changes in cardiovascular tissues suggest a novel pathway for BP regulation.
    • 2-OHOA shows promise as the first-in-class antihypertensive drug, warranting further investigation.